More than four decades on from the approval of the first biologic drug, the industry has reached a tipping point, and biotech drugs now outnumber small molecules in the global R&D pipeline. At the ...

Principal Scientist Anders Cai Holm Hansen explains how CDMO AGC Biologics uses its global, single-use network and a strategy ...

Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...

The biologics contract research organization market offers opportunities in expanding R&D outsourcing for innovative ...

Sanofi will invest $673 million annually in biologic drug development over the next two to three years, reports Reuters. The drugmaker has already spent $3.7 billion in biologics over the last five ...

Biologics are complex medications produced through biological processes or from living organisms such as proteins and genes. Biosimilars are what they sound like — similar to, but not the same as, an ...

Not long ago, solving the crystal structure of a protein required an entire PhD. Growing crystals, collecting X-ray diffraction data, and interpreting electron density maps often took years of ...

The license, which Innovent’s Altruist business said is the first of its kind, positions the CDMO to support commercial ...

Company is among the first in China's drug-device combination products sector to obtain this certification, delivering superior solutions to global clientsZero non-conformities demonstrates company's ...

PRINCETON, N.J.--(BUSINESS WIRE)--Certara, Inc., the global leader in biosimulation, today announced the release of version 20 of its Simcyp™ Physiologically-based Pharmacokinetic (PBPK) Simulator ...